

59. The composition according to claim 57, wherein the effective amount of testosterone undecanoate corresponds to a dose of about 1000 mg for a 6-week administration.
60. The composition according to claim 57, wherein the progestin is norethisterone (NET) or a derivative thereof.
61. The composition according to claim 60, wherein the progestin is a NET derivative in an effective amount that corresponds to a daily release of a NET ester between 1 and 10 mg.
62. The composition according to claim 60, wherein the progestin is a NET derivative provided in an effective amount of between 100 and 500 mg for a 6-week administration.
63. The composition according to claim 60, wherein the progestin is a NET derivative provided in an effective amount of a dose between 150 and 250 mg for a 6-week administration.
64. The composition according to claim 60, wherein the progestin is a NET ester.
65. The composition according to claim 64, wherein the NET ester is selected from the group consisting of NET enanthate and NET acetate.
66. The composition according to claim 64, wherein the NET ester is NET enanthate.

67. The composition according to claim 64, wherein the NET ester is NET acetate.
68. The composition according to claim 57, wherein the testosterone undecanoate is in a form for parenteral administration selected from the group consisting of intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection and transdermal means.
69. The composition according to claim 68, wherein the testosterone undecanoate is in a form for parenteral administration selected from the group consisting of intramuscular injection, intravenous injection and subcutaneous injection.
70. The composition according to claim 69, wherein the testosterone undecanoate is in a form for intramuscular injection.
71. The composition according to claim 57, wherein the progestin is in a form for parenteral administration selected from the group consisting of intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection and transdermal means.
72. The composition according to claim 71, wherein the progestin and testosterone undecanoate are in a form for intramuscular injection.
73. The composition according to claim 57, wherein the progestin is in a form for oral administration.

74. The composition according to claim 57, wherein said progestin and said testosterone undecanoate are formulated together as one formulation.

75. The composition according to claim 57, wherein said progestin and said testosterone undecanoate are each formulated in a separate formulation.

76. A male contraceptive composition comprising effective amounts of  
i) a norethisterone derivative (NET derivative) possessing both androgenic and estrogenic properties; and  
ii) an androgen,  
wherein the effective amounts of said androgen and said NET derivative are such that the effective levels in blood are sustained for not less than 1 week,  
and said NET derivative and said androgen are formulated for non-oral administration.

77. The composition according to claim 76, wherein said effective levels in blood are sustained for not less than 2 weeks.

78. The composition according to claim 77, wherein said effective levels in blood are sustained for not less than 4 weeks.

79. The composition according to claim 76, wherein said effective amount of said NET derivative corresponds to a dose of 100-500 mg for a 6-week administration.

80. The composition according to claim 76, wherein the androgen is a testosterone ester selected from the group consisting of testosterone propionate, testosterone undecanoate, testosterone enanthate, testosterone cypionate and testosterone buciclate.

81. The composition according to claim 80, wherein the dose of the testosterone ester corresponds to a daily release of testosterone in an amount ranging between 5 and 35 mg.

82. The composition according to claim 81, wherein the dose of the testosterone ester corresponds to a daily dose of testosterone ranging between 15 and 30 mg.

83. The composition according to claim 80, wherein the dose of the testosterone ester corresponds to a dose of testosterone ranging between 500 and 1200 mg for a 6-week administration.

84. The composition according to claim 80, wherein the testosterone ester is testosterone undecanoate.

85. The composition according to claim 76, wherein the androgen is in a form for parenteral administration selected from the group consisting of intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection and transdermal means.

86. The composition according to claim 85, wherein the androgen is in a form for parenteral administration selected from the group consisting of intramuscular injection, intravenous injection and subcutaneous injection.

87. The composition according to claim 86, wherein the androgen is in a form for intramuscular injection.

88. The composition according to claim 87, wherein the NET derivative and androgen are in a form for intramuscular injection.

89. The composition according to claim 76, wherein said NET derivative and said androgen are formulated together into one formulation.

90. The composition according to claim 76, wherein the NET derivative and the androgen are formulated in separate formulations.

91. A male contraceptive formulation comprising an effective amount of a norethisterone derivative (NET derivative) possessing both androgenic and estrogenic properties, in an effective amount such that its effective level in blood is sustained for not less than 1 week.

92. The formulation according to claim 91, wherein the effective amount of the NET derivative is such that an effective level is sustained in the blood for not less than 5 weeks.

93. The formulation according to claim 91, wherein the effective amount of the NET derivative is such that an effective level is sustained in the blood for not less than 6 weeks.
94. The formulation according to claim 91, wherein the effective amount of the NET derivative is between 100 and 500 mg for a 6-week administration.
95. The formulation according to claim 94, wherein the effective amount of the NET derivative corresponds to a dose of between 200 and 400 mg for a 6-week administration.
96. The formulation according to claim 95, wherein the effective amount of the NET derivative corresponds to a dose of between 150 and 250 mg for a 6-week administration.
97. The formulation according to claim 96, wherein the effective amount of the NET derivative corresponds to a daily release of a NET ester between 1 and 10 mg.
98. The formulation according to claim 91, wherein the NET derivative is in a form for parental administration selected from the group consisting of intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection and transdermal means.
99. The formulation according to claim 98, wherein the NET derivative is in a form for parental administration selected from the group consisting of intramuscular injection, intravenous injection and subcutaneous injection.

100. The formulation according to claim 99, wherein the NET derivative is in a form for intramuscular injection.
101. The formulation according to claim 91, wherein the NET derivative is a NET ester.
102. The formulation according to claim 101, wherein the NET ester is selected from the group consisting of NET enanthate and NET acetate.
103. The formulation according to claim 102, wherein the NET ester is NET enanthate.
104. The formulation according to claim 91, further comprising an androgen.
105. A method of providing male contraception comprising administering to a male a combination of an effective amount of
- i) a progestin possessing both androgenic and estrogenic properties; and
  - ii) testosterone undecanoate,
- wherein the testosterone undecanoate is administered by non-oral means.
106. The method according to claim 105, wherein the dose of testosterone undecanoate is between 800 and 1500 mg for a 6-week administration.
107. The method according to claim 106, wherein the dose of testosterone undecanoate corresponds to 1000 mg for a 6-week administration.

108. The method according to claim 105, said testosterone undecanoate is administered in intervals of not less than 1 week and said progestin is administered in intervals of not less than 1 week.

109. The method according to claim 105, wherein said testosterone undecanoate is administered in intervals of not less than 2 weeks and said progestin is administered in intervals of not less than 2 weeks.

110. The method according to claim 105, wherein said testosterone undecanoate is administered in intervals of not less than 4 weeks and said progestin is administered in intervals of not less than 4 weeks.

111. The method according to claim 105, wherein the progestin is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection and transdermal means and the testosterone undecanoate is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection and transdermal means.

112. The method according to claim 108, wherein the progestin is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection and transdermal means and



the testosterone undecanoate is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection and transdermal means.

**113.** The method according to claim 112, wherein the progestin is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection and subcutaneous injection and  
the testosterone undecanoate is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection and subcutaneous injection.

**114.** The method according to claim 113, wherein said progestin and said testosterone undecanoate are administered by intramuscular injection.

**115.** The method according to claim 105, wherein the progestin is administered by oral means and  
the testosterone undecanoate is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection and transdermal means.

**116.** The method according to claim 115, wherein the progestin is administered by oral means and  
the testosterone undecanoate is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection and subcutaneous injection.

117. The method according to claim 116, wherein the progestin is administered by oral means and the testosterone undecanoate is administered by intramuscular injection.

118. The method according to claim 105, wherein said testosterone undecanoate is administered simultaneously with the progestin.

119. The method according to claim 105, wherein said testosterone undecanoate is administered non-simultaneously with said progestin.

120. A method of providing male contraception comprising administering to an individual a combination of an effective amount of;

i) a norethisterone derivative (NET derivative) possessing both androgenic and estrogenic properties; and

ii) an androgen,

wherein said androgen is administered in intervals of not less than 1 week and said NET derivative is administered in intervals of not less than 1 week.

121. The method according to claim 120, wherein the interval is not less than 2 weeks.

122. The method according to claim 120, wherein the interval is not less than 4 weeks.

123. The method according to claim 120, wherein said NET derivative is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection and transdermal means.

**124.** The method according to claim 120, wherein said NET derivative is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection and subcutaneous injection.

**125.** The method according to claim 120, wherein said androgen is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection and transdermal means.

**126.** The method according to claim 120, wherein said androgen is administered by parenteral means selected from the group consisting of intramuscular injection, intravenous injection and subcutaneous injection.

**127.** The method according to claim 120, wherein said NET derivative and said androgen are administered by intramuscular injection.

**128.** The method according to claim 120, wherein said NET derivative is administered simultaneously with said androgen.

**129.** The method according to claim 120, wherein said NET derivative is administered non-simultaneously with said androgen.